Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake

Rhea-AI Filing Summary

Femasys Inc. director Kenneth D. Eichenbaum filed an initial ownership report showing a mix of common stock and convertible securities. He holds 25,010 shares of common stock directly, plus senior secured convertible notes initially convertible at $0.73 per share into up to 102,366 shares.

He also holds Series A-1, B-1 and C-1 warrants, each series initially exercisable into up to 102,366 common shares at exercise prices of $0.81, $0.92, and $1.10 per share, respectively, with stated expiration in 2035. A footnote indicates the reported securities were purchased for an aggregate of $75,000.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Eichenbaum Kenneth D.

Role Director

Type	Security	Shares	Price	Value
holding	Senior Secured Convertible Notes	--	--	--
holding	Series A-1 Warrants	--	--	--
holding	Series B-1 Warrants	--	--	--
holding	Series C-1 Warrants	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Senior Secured Convertible Notes — 102,366 shares (Direct); Series A-1 Warrants — 102,366 shares (Direct); Series B-1 Warrants — 102,366 shares (Direct); Series C-1 Warrants — 102,366 shares (Direct); Common Stock — 25,010 shares (Direct)

Footnotes (1)

1. Holder may, at its option, prior to maturity, convert all or any portion of the outstanding amount of Senior Secured Convertible Notes due 2035 (the "Convertible Notes"), including accrued paid in-kind interest thereon, subject to certain limitations, into shares of Common Stock, at an initial conversion price of $0.73 per share of Common Stock. The conversion rate is subject to adjustment in accordance with the terms of the Convertible Notes and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. Holder may, at its option, exercise the Series A-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.81 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series A-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. Holder may, at its option, exercise the Series B-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.92 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series B-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. Holder may, at its option, exercise the Series C-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $1.10 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series C-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. Represents the maximum number of shares of Common Stock issuable upon the voluntary conversion of the original stated amount of the Convertible Notes. The number of shares issuable upon conversion of the Convertible Notes is subject to increase in connection with the accrual of interest, which is payable in kind. The Holder's ability to convert the Convertible Notes to shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. The reported securities were purchased by the reporting person for an aggregate amount of $75,000.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Eichenbaum Kenneth D.

(Last) (First) (Middle)

C/O FEMASYS INC.

3950 JOHNS CREEK COURT, SUITE 100

(Street)

SUWANEE GEORGIA 30024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
FEMASYS INC [ FEMY ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25,010	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Senior Secured Convertible Notes	11/07/2025	11/07/2035	Common stock, par value $0.001 per share	102,366(5)	$0.73(1)(7)	D
Series A-1 Warrants	11/07/2025	11/07/2035	Common stock, par value $0.001 per share	102,366(6)	$0.81(2)(7)	D
Series B-1 Warrants	11/07/2025	11/07/2035	Common stock, par value $0.001 per share	102,366(6)	$0.92(3)(7)	D
Series C-1 Warrants	11/07/2025	11/07/2035	Common stock, par value $0.001 per share	102,366(6)	$1.1(4)(7)	D

Explanation of Responses:

1. Holder may, at its option, prior to maturity, convert all or any portion of the outstanding amount of Senior Secured Convertible Notes due 2035 (the "Convertible Notes"), including accrued paid in-kind interest thereon, subject to certain limitations, into shares of Common Stock, at an initial conversion price of $0.73 per share of Common Stock. The conversion rate is subject to adjustment in accordance with the terms of the Convertible Notes and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

2. Holder may, at its option, exercise the Series A-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.81 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series A-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

3. Holder may, at its option, exercise the Series B-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.92 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series B-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

4. Holder may, at its option, exercise the Series C-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $1.10 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series C-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

5. Represents the maximum number of shares of Common Stock issuable upon the voluntary conversion of the original stated amount of the Convertible Notes. The number of shares issuable upon conversion of the Convertible Notes is subject to increase in connection with the accrual of interest, which is payable in kind. The Holder's ability to convert the Convertible Notes to shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

6. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

7. The reported securities were purchased by the reporting person for an aggregate amount of $75,000.

	s/ Kathy Lee-Sepsick, Attorney-in-fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing for FEMASYS INC (FEMY) show about Kenneth D. Eichenbaum's holdings?

Kenneth D. Eichenbaum reports an initial ownership position in Femasys Inc. He directly holds 25,010 common shares, senior secured convertible notes, and three warrant series, each initially tied to up to 102,366 underlying shares of common stock at specified exercise or conversion prices.

How many FEMASYS INC (FEMY) common shares does Kenneth D. Eichenbaum directly own?

Eichenbaum directly owns 25,010 shares of Femasys common stock. This direct equity stake is reported separately from his senior secured convertible notes and Series A-1, B-1 and C-1 warrants, which are currently derivative positions linked to additional potential common shares.

What are the key terms of Kenneth D. Eichenbaum’s senior secured convertible notes in FEMY?

The senior secured convertible notes are initially convertible at $0.73 per share. They are tied to up to 102,366 underlying common shares, with the holder able to convert prior to maturity, subject to Nasdaq Capital Market limitations and standard anti-dilution adjustments.

What warrant positions in FEMASYS INC (FEMY) does Kenneth D. Eichenbaum report?

Eichenbaum reports Series A-1, B-1 and C-1 warrants in Femasys. Each series is initially exercisable into up to 102,366 common shares with exercise prices of $0.81, $0.92 and $1.10 per share, subject to Nasdaq-related limitations and standard adjustment provisions.

When do Kenneth D. Eichenbaum’s FEMASYS INC (FEMY) convertible and warrant positions expire?

The senior secured convertible notes and all three warrant series carry a 2035 expiration. The data show an expiration date of November 7, 2035, with the holder able to exercise or convert earlier, subject to the specific terms and market listing limitations.

What total purchase amount is disclosed for Kenneth D. Eichenbaum’s FEMASYS INC (FEMY) securities?

The filing states the reported securities were purchased for $75,000 in aggregate. This figure covers the combined package of senior secured convertible notes and warrants described, providing a single monetary reference for his reported derivative investment in Femasys Inc.